It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Lyme disease is a tick-borne disease caused by bacteria of the genus Borrelia. The host factors that modulate susceptibility for Lyme disease have remained mostly unknown. Using epidemiological and genetic data from FinnGen and Estonian Biobank, we identify two previously known variants and an unknown common missense variant at the gene encoding for Secretoglobin family 1D member 2 (SCGB1D2) protein that increases the susceptibility for Lyme disease. Using live Borrelia burgdorferi (Bb) we find that recombinant reference SCGB1D2 protein inhibits the growth of Bb in vitro more efficiently than the recombinant protein with SCGB1D2 P53L deleterious missense variant. Finally, using an in vivo murine infection model we show that recombinant SCGB1D2 prevents infection by Borrelia in vivo. Together, these data suggest that SCGB1D2 is a host defense factor present in the skin, sweat, and other secretions which protects against Bb infection and opens an exciting therapeutic avenue for Lyme disease.
The genetic basis of susceptibility to Lyme disease is largely unknown. Here, the authors discover a risk locus in the gene encoding the protein Secretoglobin family 1D member 2, which is expressed in skin and affects infection by the bacteria that causes Lyme disease in vitro and in vivo.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Helsinki Institute of Life Science, University of Helsinki, Institute for Molecular Medicine Finland, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071); Stanford University School of Medicine, Department of Genetics, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Helsinki University Hospital and University of Helsinki, Department of Oral and Maxillofacial Surgery, Helsinki, Finland (GRID:grid.15485.3d) (ISNI:0000 0000 9950 5666); Cleft Palate and Craniofacial Center, Helsinki University Hospital and University of Helsinki, Department of Plastic Surgery, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071)
2 Institute of Genomics, University of Tartu, Estonian Genome Centre, Tartu, Estonia (GRID:grid.10939.32) (ISNI:0000 0001 0943 7661)
3 Stanford University School of Medicine, Institute for Stem Cell Biology & Regenerative Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
4 Stanford University School of Medicine, Institute for Stem Cell Biology & Regenerative Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Massachusetts Institute of Technology, Department of Biological Engineering, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786)
5 Massachusetts Institute of Technology, Department of Biological Engineering, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786)
6 Helsinki Institute of Life Science, University of Helsinki, Institute for Molecular Medicine Finland, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071)
7 Stanford University School of Medicine, Institute for Stem Cell Biology & Regenerative Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Massachusetts Institute of Technology, Department of Biological Engineering, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); University of Illinois at Chicago, Richard and Loan Hill Department of Biomedical Engineering, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319)
8 Internal Medicine Clinic, Tartu University Hospital, Department of Infectious Diseases, Tartu, Estonia (GRID:grid.412269.a) (ISNI:0000 0001 0585 7044)
9 Helsinki Institute of Life Science, University of Helsinki, Institute for Molecular Medicine Finland, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071); Stanford University School of Medicine, Department of Genetics, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Fred Hutchinson Cancer Center, Herbold Computational Biology Program, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622)
10 University of Helsinki, Organismal and Evolutionary Biology Research Program, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071)
11 Helsinki Institute of Life Science, University of Helsinki, Institute for Molecular Medicine Finland, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071); Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623); Massachusetts General Hospital, Center for Genomic Medicine, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Massachusetts General Hospital and Harvard Medical School, Anesthesia, Critical Care, and Pain Medicine, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)